Across TCGA pan-cancer cohorts, FAM162B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM162B data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher FAM162B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FAM162B expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC and LUAD are the cancer types where FAM162B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	1.000	0.697	.027	8	view →
LUAD	DFS	Tertile	II,III,IV	0.527	1.000	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: FAM162B tumor-vs-normal RNA expression · all FAM162B data types